Investment Thesis
Shuttle Pharmaceuticals faces critical financial distress with only $334K cash while burning $9.5M annually, creating severe going concern risk within weeks. Minimal revenue of $100K with zero growth and $11.9M operating losses indicate failed drug commercialization. The current ratio of 0.06x signals inability to meet short-term obligations, positioning the company for restructuring or insolvency.
Strengths
- Debt-to-equity ratio of 0.19x limits leverage exposure relative to equity base
- Total liabilities of $8.2M provide some liquidation value potential
- Pharmaceutical IP portfolio may retain acquisition value in restructuring
Risks
- Cash runway of approximately 2 weeks at current $9.5M annual burn rate
- Current ratio of 0.06x indicates acute liquidity crisis and inability to service current liabilities
- Zero revenue growth and minimal $100K annual revenue suggests complete commercialization failure
- Operating cash burn unsustainable without immediate capital infusion or strategic transaction
- Negative interest coverage of -14.3x indicates operational inability to service debt
- No insider Form 4 activity in 90 days reflects lack of management confidence
Key Metrics to Watch
- Cash balance and weeks of runway remaining
- Quarterly revenue and operating cash burn trajectory
- Current ratio and working capital adequacy for debt covenant compliance
- Clinical trial progression and regulatory pathway for pipeline assets
Financial Metrics
Revenue
100.0K
Net Income
-11.7M
EPS (Diluted)
$-7.16
Free Cash Flow
-9.5M
Total Assets
10.5M
Cash
334.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-11,916.8%
Net Margin
-11,721.7%
ROE
-519.9%
ROA
-111.9%
FCF Margin
-9,500.7%
Balance Sheet & Liquidity
Current Ratio
0.06x
Quick Ratio
0.06x
Debt/Equity
0.19x
Debt/Assets
78.5%
Interest Coverage
-14.32x
Long-term Debt
426.2K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T21:06:26.871416 |
Data as of: 2025-12-31 |
Powered by Claude AI